Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Head and Neck Oncology
  •  Carcinomas
  •  Pancreatic Cancer
  •  Endometrial Cancer
  •  Hormone Therapy
  •  Blood Cancer
  •  Adjuvant Therapy
  •  Radiological Techniques and Scans

Abstract

Citation: Clin Oncol. 2017;2(1):1246.DOI: 10.25107/2474-1663.1246

The Effect of Corticosteroid Eye Drops on the Prevention of Eye Disorders Caused by High-Dose Cytarabine Therapy

Tetsuo Kume, Kana Akiyama, Shigeyo Sakata, Takahiro Mochizuki, Ikue Shiki, Satoshi Motokawa, Michihiro Shino and Takashi Ikeda

Department of Pharmacy, Shizuoka Cancer Center, Japan
Department of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Japan
Department of Pharmacy, Kushiro City General Hospital, Japan

*Correspondance to: Tetsuo Kume 

 PDF  Full Text Research Article | Open Access

Abstract:

Side effects of high-dose cytarabine (HDCA) treatment include cytarabine syndrome with symptoms such as fever, muscle pain, and conjunctivitis. The use of corticosteroid eye drops to prevent eye disorders caused by HDCA has been previously reported. However, previously reported prophylactic methods include the administration of corticosteroid eye drops combined with other eye droups, we retrospectively examined the prophylactic effect of 0.1% fluorometholone eye drops (FM) as a monotherapy to prevent eye disorders caused by HDCA. The subjects were hospitalized patients who received HDCA at doses of at least 1 g/m2 between April 2011 and December 2014 at a Japanese cancer treatment center. Patients taking HDCA once a day received FM every 6 h in both eyes, starting from the first HDCA dose and continuing until 48 h after the last dose. Patients taking HDCA twice a day were administered FM every 4 h in both eyes, starting from the first HDCA dose and continuing until 48 h after the last dose. The incidence of Grade 1 and Grade 2 eye disorders was 2.8% and 2.3%, respectively, and Grade 3 eye disorders were not detected. The use of FM as a single agent appears to prevent eye disorders caused by HDCA, with the added advantage that it is a simple technique, which can be managed by the patients themselves.

Keywords:

Eye disorders; Fluorometholone eye drops; High-dose cytarabine; Prophylactic effect; Simple technique

Cite the Article:

Kume T, Akiyama K, Sakata S, Mochizuki T, Shiki I, Motokawa S, et al. The Effect of Corticosteroid Eye Drops on the Prevention of Eye Disorders Caused by High-Dose Cytarabine Therapy. Clin Oncol. 2017; 2: 1246.

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

High WT1 Expression Associates with Unfavorable Prognosis in Acute Myeloid Leukemia
 Abstract  PDF  Full Text
Systematic Review and Meta-Analysis of PD-1 and CTLA-4 Bispecific Antibody in the Treatment of Gastric Cancer
 Abstract  PDF  Full Text
View More...